NCT05553600

Brief Summary

This prospective multi-center, open-label, randomized, cross-over study is designed to validate the user needs of a tampon design. The hypothesis is that user needs are met.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
732

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Oct 2022

Shorter than P25 for not_applicable

Geographic Reach
1 country

9 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 16, 2022

Completed
7 days until next milestone

First Posted

Study publicly available on registry

September 23, 2022

Completed
28 days until next milestone

Study Start

First participant enrolled

October 21, 2022

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 5, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 5, 2023

Completed
9 months until next milestone

Results Posted

Study results publicly available

January 17, 2024

Completed
Last Updated

January 17, 2024

Status Verified

December 1, 2023

Enrollment Period

7 months

First QC Date

September 16, 2022

Results QC Date

November 14, 2023

Last Update Submit

December 20, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • The Percentage of Used Tampons That Have Elongated

    The percentage of used tampons within each test code that have elongated \>10mm. The denominator for the percentage calculation is based upon the number of used tampons returned within each test code.

    At the end of 1 menstrual period (up to 10 days) for each intervention

Secondary Outcomes (7)

  • Validation of Performance User Needs Based on Participant Diary Responses.

    At the end of 1 menstrual period (up to 10 days) for each intervention

  • Validation of Performance User Needs Based on Participant Diary Responses

    At the end of 1 menstrual period (up to 10 days) for each intervention

  • Validation of Packaging/Labeling User Needs Based on Interview Responses

    At baseline, prior to any interventions

  • Number of Subjects That Had Any Lesions Noted During Gynecological Exam

    Within 72 hours prior expected menstruation (pre-use) and within 72 hours after last tampon use (post-use) for each intervention

  • Additional Gynecological Exam Results: Pre-use Vaginal pH

    Within 72 hours prior expected menstruation (pre-use) and within 72 hours after last tampon use (post-use) for each intervention

  • +2 more secondary outcomes

Study Arms (2)

Regular Absorbency

OTHER

Modified regular absorbency tampon versus regular absorbency reference tampon

Device: Tampon BRDevice: Tampon CR

Super Absorbency

OTHER

Modified super absorbency tampon versus super absorbency reference tampon

Device: Tampon BSDevice: Tampon CS

Interventions

Tampon BRDEVICE

Modified Regular Absorbency Tampons

Regular Absorbency
Tampon CRDEVICE

Reference Regular Absorbency Tampons

Regular Absorbency
Tampon BSDEVICE

Modified Super Absorbency Tampons

Super Absorbency
Tampon CSDEVICE

Reference Super Absorbency Tampons

Super Absorbency

Eligibility Criteria

Age18 Years - 49 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Willing and able to read and provide written informed consent.
  • Female in good general health, age 18-49 (inclusive).
  • History of regular menstrual cycles during the previous 3months lasting approximately 21-35 days, including at least 4 days of menstruation, and expecting to menstruate during the study period.
  • History of use of applicator tampons without discomfort.
  • Normally use at least 6 tampons for protection during menstruation.
  • Normally uses regular, super, and/or super plus absorbency tampons for menstrual protection.
  • Agrees to the conduct of all study procedures, including gynecological exams (if applicable), and agrees to follow all study instructions and return for scheduled appointments.
  • Has used an acceptable form of birth control for at least one month prior to enrollment and for the duration of the study.

You may not qualify if:

  • Pregnant, lactating or is trying to become pregnant.
  • Less than six (6) weeks post-partum.
  • Has a menstrual abnormality (such as oligomenorrhea or amenorrhea).
  • Has a known allergy or sensitivity to components of the investigational products, including rayon.
  • Any other medical condition or history, as determined by the Investigator that could compromise the study results or subject safety.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (9)

Del Sol Research Management, LLC

Tucson, Arizona, 85715, United States

Location

Agile Clinical Research Trials, LLC

Atlanta, Georgia, 30328, United States

Location

Velocity Clinical Research

Boise, Idaho, 83642, United States

Location

Best Clinical Trials, LLC

New Orleans, Louisiana, 70115, United States

Location

Princeton Consumer Research

Raritan, New Jersey, 08869, United States

Location

Velocity Clinical Research

Anderson, South Carolina, 29621, United States

Location

Velocity Clinical Research

Greenville, South Carolina, 29615, United States

Location

Signature Gyn Services

Fort Worth, Texas, 76104, United States

Location

TMC Life Research, Inc.

Houston, Texas, 77054, United States

Location

Results Point of Contact

Title
Jin Zhang
Organization
Kimberly-Clark Corporation

Publication Agreements

PI is Sponsor Employee
No
Restriction Type
OTHER
Restrictive Agreement
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
OTHER
Intervention Model
CROSSOVER
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 16, 2022

First Posted

September 23, 2022

Study Start

October 21, 2022

Primary Completion

May 5, 2023

Study Completion

May 5, 2023

Last Updated

January 17, 2024

Results First Posted

January 17, 2024

Record last verified: 2023-12

Data Sharing

IPD Sharing
Will not share

Locations